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A stability-indicating LC method was validated for the quantification of midazolam (MDZ) active pharmaceutical ingredient 
(API) and in pharmaceutical formulations. Isocratic chromatography was performed on C18 column with mobile phase containing 
methanol/acetonitrile/water (45:35:20 v/v/v) with 0.4% of triethylamine pH 6.5. The validation included specificity, linearity, 
accuracy, precision and robustness. In specificity, after hydrolytic (acid, basic, water), oxidant and thermal degradation, it was 
found that the concentration of MDZ decreased substantially, with the appearance of peaks representatives of the degradation 
products, proving the stability-indicating potential of the method. The response was linear in the range 50.0 – 250.0 µg.mL-1, with 
11.73 µg.mL-1 and 3.87 µg.mL-1 as LOQ and LOD, respectively. Recoveries ranged between 98.68 and 100.41%. The relative 
standard deviation values for intra and interday precision were 1.11% (day 1), 0.82% (day 2) and 1.47% (day 3), respectively. The 
tablets and injections containing MDZ were approved in the assay and content uniformity. The method can be adopted by 
pharmacopeias and for routine quality control for analysis of MDZ API, tablets and injection. 




Pharmacological sedation and anxiolysis is a common 
practice in anesthesia and the anesthetics used should be 
easy of application, rapid action, short duration action (short 
half-life), and few adverse events. Benzodiazepines are the 
safest class of drugs for this purpose. In this context, MDZ 
has all these characteristics, hence is the most commonly 
used in anesthetic procedures of hospitals (1,2,3). MDZ 
exhibits anticonvulsant, anxiolytic, muscle relaxant and 
sedative properties, used in sleep disorder or induction of 
anesthesia, orally, intravenously or intramuscularly routes. It 
reduces behavioral problems in postoperative with presence 
of anterograde amnesia induced (4). MDZ acts on the central 
nervous system (CNS) potentiating the effects of Gamma- 
aminobutyric acid (GABA agonist) which is the main 
inhibitor  of the  CNS (5,6). 
This compound is a weak acid with a pKa of 6.2 in water 
(4). The solubility in water is approximately 10.3 mg.mL-1 
(pH 3.4, 25°C) (7). MDZ is available commercially in tablet 
and injection  forms  (8). 
Several methods by LC are described for MDZ 
quantification and its metabolites in biological matrices of 
humans, rats and rabbits plasma (9, 10), as well methods to 
evaluate the quality of pharmaceutical formulations, 
compiled in the review (11). The British Pharmacopoeia 
describes the monograph for MDZ active pharmaceutical 
ingredient (API) and for injections. API assays have been 
performed by titration, being unable to detect degradation 
products (12). The pharmacopeias do not describe the 
monograph to evaluate tablets. Furthermore, to detect 
degradation products it is require more sensitive techniques. 
The Brazilian Pharmacopeia does not present monographs 
for  MDZ  for  any  of  that  forms,   included   the   API. 
ICH (13) recommends that a method should be able to detect 
degradation products from stress test or impurities, but these 
degradations products should not interfere in the 
quantification of the drug. 
In this way, the aim of the work was to develop and validate 
a stability-indicating method by LC for the quantification of 
MDZ and its application in tablets and injections. The 




Chemicals and materials 
 
MDZ API was purchased from Fagron, São Paulo/SP/Brazil, 
and the purity was determined by titration (12) (Titrino 702 
SM, Methrom Pensalab, São Paulo/SP/Brazil) being 99.5% 
± 0.83%. The tablets (15 mg MDZ, Roche, 
Jaguaré/SP/Brazil) and injections (50 mg.mL-1 MDZ, União 
Química, São Paulo/SP/Brazil) were kindly donated by 
Hospital São Vicente de Paulo, Passo Fundo, Rio Grande do 
Sul, Brazil. The reagents used were HPLC grade. The water 
type 1 was obtained in Direct-Q system from Millipore®. 
 
Instruments and analytical conditions 
 
LC system consisted of a Flexar Perkin Elmer (Shelton/CT/ 
USA) liquid chromatography, equipped with binary pump, 
PDA  detector  in  235  nm,  and  autosampler  with injection 
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volume of 20 µL. The chromatograph separation was carried 
out using a reversed phase column Brownlee C18 (250 mm x 
4.6 mm, 5 µm). 
The mobile phase consisted of methanol:acetonitrile:water 
(45:35:20 v/v/v) with 0.4% triethylamine and pH adjusted to 
6.5 with phosphoric acid. The elution was isocratic with a 
flow rate of 1.0 mL.min-1. The peak areas were integrated 
automatically by software Chromera Flexar. 
 
Preparation of MDZ Solution 
 
A stock standard solution of 500.0 µg.mL-1 was prepared by 




For the validation of the method the following parameters 
were studied: specificity, linearity, limit of quantitation 
and detection, accuracy, precision and robustness (13) 




In order to determine the specificity, MDZ solutions (500.0 
µg.mL-1)   were    submitted    to    forced    degradation.  
The acid, alkaline and neutral degradation were performed 
by diluting the sample in 0.1 mol.L-1 HCl, 0.1 mol.L-1 NaOH, 
and purified water, respectively at room temperature for 6 
days. Oxidative degradation was induced by storing the 
sample diluted with 30% hydrogen peroxide at room 
temperature for 6 days, protected from light. To investigate 
drug stability under thermal stress, the solution was kept in 
an oven at 80°C for 3 days. The photolysis studies were 
conducted through the exposure of solutions under 254 nm 
UV light for 7, 12 and 25 days. After the procedures, the 
samples were neutralized and diluted with methanol to a 
final concentration of 150.0 µg.mL-1 and analyzed. 
Photolysis degradation kinetic was performed. To determine 
the order reaction three graphs were constructed: Percentage 
degradation versus time (days) (order zero), log of the 
percentage of degradation versus time (days) (first order); 1/ 
concentration (%) versus time (days) (second order). The 
best correlation coefficient of the straight line (r) defines the 
order of the reaction (14). After the definition of the order 
reaction, it was possible to calculate the K (degradation rate 
constant, days-1) (equation 1), and t50% (half-life in this 
condition, namely the time required for degrading 50% 
drug) (equation 2). 
K = C0 - C / T (1) 
t50% = C0 / 2 K (2) 
Where "C0" is the initial concentration and "C" is the last 
measured concentration at time "t". 
Linearity, Limits of detection (LOD) and quantitation 
(LOQ) 
 
Linearity was determined by preparing of three calibration 
curves containing five concentration of MDZ (50.0, 100.0, 
150.0, 200.0 e 250.0 µg.mL-1) in methanol. The injections 
were made in triplicate to verify the repeatability of the 
detector response. The peak areas of the chromatograms 
were plotted versus the concentration to obtain the 
calibration curve. The curves were subjected to ANOVA (P 
< 0.05) observing the sources of variations linear regression 
and linearity deviation. 
The LOD and LOQ were calculated from the slope and 
standard deviation of the intercept of the mean of three 
calibration curves. 
 
Accuracy and Precision 
 
The accuracy of the developed method was evaluated by a 
recovering test, by analysis of three MDZ concentrations of 
60.0 µg.mL-1, 140.0 µg.mL-1 and 240.0 µg.mL-1 within the 
range of the curve, performed in triplicate. The % recovery 
was calculated by equation 3: 
% Recovery = (found concentration) / (theoretical 
concentration) x 100 (3) 
 
 
The intraday precision was evaluated analyzing six MDZ 
solutions of 140.0 µg.mL-1 during the same day, under the 
same experimental conditions. Interday precision was 
evaluated analyzing the solutions on three different days. 
Peak areas were determined and compared. Precision was 




The robustness was established by introducing small 
changes in the chromatographic system, like flow rate (0.9 
mL.min-1 and 1.1 mL.min-1) and the pH of the mobile phase 
(6.3 and 6.7). 
 
Method Application 
Assay of the MDZ tablets and injections 
 
For quantification of the MDZ in tablets (containing 15 mg 
MDZ), 20 tablets were weighted and mashed obtaining a 
pool. A content equivalent to 15 mg of MDZ was added to a 
100 mL volumetric flask and diluted with methanol, in 
triplicate. Before of injection to the LC system, the solutions 
were filtered.  The concentration of the final solutions was 
150.0 µg. mL-1. 
For quantification of the MDZ injections, 20 ampoules 
(containing 50.0 µg.mL-1 MDZ) were mixed. An aliquot of 
200 µL of the mixture was added to a 10 mL volumetric 
flask diluted with methanol or saline solution, in triplicate. 
Aliquots (1.5 mL) were removed and added to a 10 mL 
volumetric flask obtaining a final concentration of 150.0 µg. 
mL-1. The saline solution was used to investigate the  
stability of the drug in this diluent commonly used in 
hospitals. The results were analyzed statistically using 
Student t test (P < 0.05). 




Uniformity of Content 
 
To perform the uniformity of content 10 tablets and 10 
injections of the same batch were analyzed separately. Each 
tablet (containing 15 mg of MDZ) was added individually to 
100 mL volumetric flasks diluted with methanol, obtaining 
the final concentration of 150.0 µg.mL-1. For the injections 
(50 mg.mL-1) 200 µL were pipetted individually of each 
injection, added to volumetric flask and completed to 10 mL 
with methanol. An aliquot of 1.5 mL was replaced to 10 mL 
volumetric flask, to obtain a final concentration of 150.0 
µg.mL-1. The solutions were injected into the LC and the 
amount of drug was calculated by comparing with a 
calibration curve prepared on the same day. The acceptance 
value (AV) was calculated according to British 
Pharmacopoeia (12). 
 
Results and discussion 
Development and Validation of Method 
 
The composition of mobile phase was optimized to obtain a 
better chromatographic condition in a short time of 
separation. The best peak asymmetry was achieved with a 
flow rate of 1.0 mL.min-1 with methanol:acetonitrile:water 
(45:35:20 v/v/v) with 0.4% trielthylamine pH 6.5 as mobile 
phase. The retention time was about 4 minutes, and a typical 
chromatogram obtained is shown in fig 1. 
 
 
Figure 1. Chromatograms obtained under stress studies. a) MDZ 
IPA solution (150 µg.mL-1); b) After neutral hydrolysis; c) After 
acid hydrolysis; d) After alkaline hydrolysis; e) After oxidative 
degradation; f) After thermal degradation; g) After 25 days of 
exposure in UV light. Chromatographic conditions: C18 column, 
mobile phase consisting of methanol: acetonitrile: water (45:35:20 
v/v/v) with 0.4% triethylamine pH 6.5 under flow rate of 1.0 
mL.min-1 and UV detection at 235 nm. 
The system suitability results showed that the parameters are 
appropriate and able to produce reliable data. The 
asymmetry, number of theoretical plates and peak area ± 
RSD (%) were 1.412 ± 0.075, 4,912 ± 1.65 and 




The specificity of the method was confirmed by forced 
degradation (fig 1). From the results of acid, basic, neutral 
hydrolysis and oxidation during 6 days, the concentration of 
MDZ decreased 15.36%, 9.55%, 49.84%, 31.95%, 
respectively, with the appearance of discrete additional 
peaks. The thermal stress reduced in 50.38% the MDZ 
concentration, with the appearance of additional peaks 
related to degradation products. 
Under UV light, the degradation of MDZ was 32.9%, 47.3% 
and 85.3% after 7, 12 and 25 days of exposition, 
respectively. 
The graphs were constructed to determine the kinetics of 
photolysis degradation, obtaining the correlation coefficient: 
order zero (r = 1), first order (r = 0.9850), second order (r = 
0.9594). In this way, the reaction follows zero order kinetics 
i.e., the degradation independent of the concentration of the 
reactants, and is in constant rate (14). The t50% was 14.65 
days. The low value of t50%, show that the MDZ solutions are 
unstable when exposed to UV light. To avoid this 
degradation, the manufacturers, particularly of the 
injections, should use amber glass vials. 
Forced degradation showed higher degradation of MDZ in 
thermal and neutral condition, followed by acidic and basic. 
The stability of MDZ solutions was investigated under 
mercury lamp and day light (15). From their experiments, 
they noticed the presence of deteriorated products: 6-(8- 
chloro-1-methyl-4,5-dihydro-2,5,10 b-triazabenzo) 
[e]azulen-6-ylidene)-cyclohexa-2,4-dienone and 6-chloro-2- 
methyl-4-(2-fluorophenyl)-quinazoline and 6-chloro-2- 
methyl-4(1H)-quinazolinone. 
Moreover, the aqueous MDZ solutions were evaluated under 
different pH. The solutions into pH 2 and 3 preserve the 
diazepine ring open, which stabilizes the solution against 
photo decomposition. On the other hand, the ring of MDZ 
molecule closes when submitted to pH over 4, which it is 
less stable and it can be decomposed under light. Therefore, 
the solutions must be stored in the absence of light (avoiding 
the photodecomposition) and may be manufactured at the 
minimum pH allowed (15). 
 
Linearity, LOD and LOQ 
 
The linearity of the method was demonstrated by the 
correlation coefficient (r) obtained by linear regression 
analysis of the calibration curve (n=3). The equation was y = 
60.890 x + 170.328 and r obtained was 0.9995. The method 
was linear in the range from 50.0 - 250.0 µg.mL-1. ANOVA 
demonstrated significant linear regression and absence of 
linearity deviation (P < 0.05). LOQ and LOD calculated 




were 11.73 µg.mL-1 and 3.87 µg.mL-1 respectively, which 
indicate the adequate sensitivity of the method. 
 
Accuracy and Precision 
 
Table 1 shows the accuracy from the recovery (%) of MDZ 
at three concentrations and the mean recovery was 99.61%. 
 
 
Table 1. Results from the recovery test, intra-day and inter-day 
precision and range investigated during robustness testing for 





% Found Concentration Concentration (µg.mL-1) 
recovery (µg.mL-1)  
98.68 59.2 60 
100.41 140.58 140 
99.75 239.43 240 
 
 
Intraday and Interday Precision (n=6) 
Assay and Uniformity Content of MDZ tablets and 
injections 
 
The tables (n = 20) presented a mean content of 98.02% (SD 
± 0.85) and injections diluted in saline solution or methanol 
a content of 98.04% (SD ± 1.85) and 98.71% (SD ± 1.41), 
respectively. The results from analysis of injections 
injections were compared by Student's t test (0.455 < 2.92, P 
< 0.05), presenting no difference significant between the 
solvents methanol and saline in the content of MDZ, when 
these solutions are freshly prepared. The saline solution did 
not decrease the MDZ concentration in injections, i.e., it 
does not modify the stability of the drug. This result is 
important because the MDZ solutions were generally diluted 
in saline solution, and remains in this condition by hours 
during the infusions in patients. 
These results for assay of MDZ showed satisfactory results. 
There are not specifications for tablets, only for injections. 
In this case, the content obtained was in accordance within 
the specifications (contains not less than 98.5% and not 
more than 101.5% of the declared amount of MDZ) (12). 
Uniformity content of MDZ tablets and injections showed to 
be in accordance within the specifications. For the 
calculation of uniformity content, the following equation 

















AV = k. s (12) 
 
Where "s" is the standard deviation and "k" is the 
acceptability constant (equal to 2.4). 
The mean (%) ± SD for MDZ tablets and injection was: 
99.95 ± 3.80 and 100.83 ± 1.34. The AV were 9.13 and 3.22 
for tablets and injections, respectively, lower than L1 (L1 = 
15), which is consistent with the recommendations, 


















The repeatability (intraday) and intermediate precision 
(interday) of the method were determined, and the results 
were expressed as RSD. All data (table 1) were in 




There were no differences in the levels of MDZ found in the 
tested conditions (table 1), confirming the robustness. The 
variations in the mobile phase did not alter the retention time 
and the quantification of the drug. 
The validation proved the specificity, linearity, sensibility, 
accuracy, precision and robustness. From the results 
obtained, the method development proved to be appropriate 
for assay of API, tablets and injections by LC and is capable 
to be used in daily routine of quality control laboratories. 
The literature does not report methods for quality control of 
tablets, and Brazilian Pharmacopeia does not present any 
monographs     for      quality      analysis      of      MDZ. 
The developed method is indicative of stability, and it is  
able to quantify MDZ in presence of its degradation 
products. The results obtained from the forced degradation 
have shown that MDZ is unstable under hydrolysis 
(specialty neutral), thermal and UV light. In UV light, the 
degradation was about 30% in 7 days, demonstrating the 
importance to avoid the drug exposition. 
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